Skip to Content

EHA24: New Treatment Regimen Marks a Breakthrough for Patients with Multiple Myeloma

The use of Isa-VRd as a new standard-of-care option for frontline disease control in patients aged ≤80 with transplant-ineligible NDMM.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top